The complexity of inter and intra-tumor variability is only partially epitomized by routinely applied principal clinical parameters (patient age, lymph node involvement, neoplasm size, tumor stage and grading) and pathobiological markers such as estrogen receptors (ER), progesterone receptors (PR), and human epidermal growth factor receptor 2 (HER2/ERBB2) [55]. This evidence concerns the gene ERBB2 and neoplasm.